Cargando…

Mavrilimumab for severe COVID-19 – Authors' reply

Detalles Bibliográficos
Autores principales:	De Luca, Giacomo, Cavalli, Giulio, Campochiaro, Corrado, Della-Torre, Emanuel, Dagna, Lorenzo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837188/ https://www.ncbi.nlm.nih.gov/pubmed/33521663 http://dx.doi.org/10.1016/S2665-9913(20)30308-8

Ejemplares similares

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020)

GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study
por: De Luca, Giacomo, et al.
Publicado: (2020)

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2021)

Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
por: Cavalli, Giulio, et al.
Publicado: (2020)

Anakinra for patients with COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Serum IgG4 elevation in hyper-inflamed COVID-19 patients. Author's reply
por: Della-Torre, Emanuel, et al.
Publicado: (2022)

Myocarditis: An Interleukin-1-Mediated Disease?
por: De Luca, Giacomo, et al.
Publicado: (2018)

Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
por: Della-Torre, Emanuel, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia – Authors' reply
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19 – Authors' reply
por: Hayem, Gilles, et al.
Publicado: (2020)

The conundrum of interleukin-6 blockade in COVID-19
por: Campochiaro, Corrado, et al.
Publicado: (2020)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Host or pathogen-related factors in COVID-19 severity? – Authors' reply
por: Okell, Lucy C, et al.
Publicado: (2020)

Microvascular disease in diabetes and severe COVID-19 outcomes – Authors' reply
por: Colhoun, Helen M, et al.
Publicado: (2021)

Cancer and COVID-19 – Authors' reply
por: Kuderer, Nicole M, et al.
Publicado: (2020)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
por: Tomelleri, Alessandro, et al.
Publicado: (2018)

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease
por: Cavalli, Giulio, et al.
Publicado: (2019)

Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement
por: De Luca, Giacomo, et al.
Publicado: (2021)

Provision of holistic care after severe COVID-19 pneumonia – Authors' reply
por: D'Cruz, Rebecca F, et al.
Publicado: (2021)

Severe COVID-19 as a virus-independent immunothrombotic process – Authors' reply
por: McGonagle, Dennis, et al.
Publicado: (2022)

Multiomics single timepoint measurements to predict severe COVID-19 – Authors' reply
por: Garapati, Kishore, et al.
Publicado: (2023)

Antipsychotics and COVID-19: the debate goes on – Authors' reply
por: De Picker, Livia, et al.
Publicado: (2021)

COVID-19 in patients with HIV – Authors' reply
por: Miró, José M, et al.
Publicado: (2020)

COVID-19 and preterm birth – Authors' reply
por: Choudhary, Rahul, et al.
Publicado: (2021)

Neuropsychiatric disorders and COVID-19 – Authors' reply
por: Taquet, Maxime, et al.
Publicado: (2021)

COVID-19 and myocardial infarction – Authors' reply
por: Katsoularis, Ioannis, et al.
Publicado: (2021)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

COVID-19 research in LMICs – Authors' reply
por: Torres, Irene, et al.
Publicado: (2021)

Authors' Reply
por: Wendler, David, et al.
Publicado: (2006)

Combining immunomodulators and antivirals for COVID-19 – Authors' reply
por: Almansa, Raquel, et al.
Publicado: (2021)

Nailfold capillaroscopy findings in patients with coronavirus disease 2019: Broadening the spectrum of COVID-19 microvascular involvement()
por: Natalello, Gerlando, et al.
Publicado: (2021)

Pathophysiology of COVID-19-associated acute respiratory distress syndrome – Authors' reply
por: Grasselli, Giacomo, et al.
Publicado: (2021)

Ethnic disparities in COVID-19: increased risk of infection or severe disease? – Authors' reply
por: Mathur, Rohini, et al.
Publicado: (2021)

Moving towards a precision approach for prevention of severe COVID-19 – Authors' reply
por: Agrawal, Utkarsh, et al.
Publicado: (2023)

The Authors' Reply
por: Carrat, Fabrice, et al.
Publicado: (2022)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_63hurk942iv9bcf2nhn7kt5f5d